ARTES Steps Further Into the Vaccine Business by Acquiring Anavax

ARTES Biotechnology announced the acquirement of the ANAVAX virus-like particle (VLP) technology from Select Vaccines Ltd. ANAVAX is a patent-protected VLP technology that can be applied to the prevention of several infectious diseases.

This content was submitted directly to this website by the supplier.

With the combination of two excellent technology platforms, ANAVAX and the Hansenula expression system, ARTES has positioned itself as a unique partner for the vaccine industry.

The ANAVAX VLP platform has already been applied to the development of adjuvant-free vaccines against avian and swine flu, malaria and HIV. Hansenula is the preferred technology for affordable mass vaccination and is recommended by the WHO for hepatitis B vaccination campaigns. Together, the platforms build a new approach to low-cost mass production of safe and effective vaccines. ARTES' business plan is to enhance its position as a preferred development partner for vaccine manufacturer.
Companies in this article
More in Home